Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis : Narrative Review
(2023) In Dermatology and Therapy 13(10). p.2171-2185- Abstract
Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet needs that disadvantage both patients and healthcare professionals. Biosimilars are a cost-effective alternative to off-patent... (More)
Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet needs that disadvantage both patients and healthcare professionals. Biosimilars are a cost-effective alternative to off-patent biologic therapies, and there is mounting evidence to suggest they offer a valuable pharmacoeconomic strategy to lower healthcare costs in patients with psoriasis. Furthermore, the introduction of biosimilars can increase the number of patients able to receive biologics, allowing these patients to be treated earlier in the disease course, potentially modifying the course of their disease and reducing the risk of comorbidities. In time, the emergence of additional data, particularly those related to long-term safety, efficacy in extrapolated indications and the effects of switching, should reassure physicians and help overcome the final hurdles for a wider implementation of biosimilars. This review aims to provide an overview of current treatment approaches for patients with moderate-to-severe psoriasis in the biosimilars era and explores both the current challenges and potential opportunities to improve access to high-quality, effective treatments.
(Less)
- author
- Girolomoni, Giampiero ; Savage, Laura ; Gisondi, Paolo ; Svensson, Åke LU ; Mahé, Emmanuel ; Augustin, Matthias and Puig, Luis
- organization
- publishing date
- 2023-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biologic drugs, Biosimilars, Moderate-to-severe, Psoriasis, Unmet needs
- in
- Dermatology and Therapy
- volume
- 13
- issue
- 10
- pages
- 15 pages
- publisher
- Springer
- external identifiers
-
- pmid:37710078
- scopus:85170839520
- ISSN
- 2193-8210
- DOI
- 10.1007/s13555-023-01014-x
- language
- English
- LU publication?
- yes
- id
- c172ab1c-bae3-4659-8e38-f44fdc46c221
- date added to LUP
- 2023-12-08 10:18:50
- date last changed
- 2024-04-21 05:19:51
@article{c172ab1c-bae3-4659-8e38-f44fdc46c221,
abstract = {{<p>Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet needs that disadvantage both patients and healthcare professionals. Biosimilars are a cost-effective alternative to off-patent biologic therapies, and there is mounting evidence to suggest they offer a valuable pharmacoeconomic strategy to lower healthcare costs in patients with psoriasis. Furthermore, the introduction of biosimilars can increase the number of patients able to receive biologics, allowing these patients to be treated earlier in the disease course, potentially modifying the course of their disease and reducing the risk of comorbidities. In time, the emergence of additional data, particularly those related to long-term safety, efficacy in extrapolated indications and the effects of switching, should reassure physicians and help overcome the final hurdles for a wider implementation of biosimilars. This review aims to provide an overview of current treatment approaches for patients with moderate-to-severe psoriasis in the biosimilars era and explores both the current challenges and potential opportunities to improve access to high-quality, effective treatments.</p>}},
author = {{Girolomoni, Giampiero and Savage, Laura and Gisondi, Paolo and Svensson, Åke and Mahé, Emmanuel and Augustin, Matthias and Puig, Luis}},
issn = {{2193-8210}},
keywords = {{Biologic drugs; Biosimilars; Moderate-to-severe; Psoriasis; Unmet needs}},
language = {{eng}},
number = {{10}},
pages = {{2171--2185}},
publisher = {{Springer}},
series = {{Dermatology and Therapy}},
title = {{Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis : Narrative Review}},
url = {{http://dx.doi.org/10.1007/s13555-023-01014-x}},
doi = {{10.1007/s13555-023-01014-x}},
volume = {{13}},
year = {{2023}},
}